fluticasone furoate/vilanterol vs Umeclidinium/Vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline

fluticasone furoate/vilanterol · Breo Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Partial signal

NCT01313676 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 16,568 participants, with all-cause mortality as an objective clinical primary endpoint. However, the fluticasone furoate/vilanterol versus placebo comparison did not meet statistical significance (hazard ratio 0.878, p=0.137), and the record does not report a power calculation.

Reported efficacy

Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants (missed)

Result source: NCT01313676

Umeclidinium/Vilanterol

Marketed by GlaxoSmithKline and partners

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Reliable signal

NCT01777334 · Phase 3 · completed

The trial randomly assigned 905 participants and used double blinding with tiotropium as an active comparator. Its primary endpoint was the clinical lung-function measure trough FEV1, and the primary comparison significantly favored umeclidinium/vilanterol.

Reported efficacy

Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115) (met)

Result source: NCT01777334

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​vilanterolUmeclidinium/​Vilanterol
Moderate or severe exacerbations, annualised rate—Not reported—Trial running · NCT06474039
Trough FEV1, change—Not reported0.2 vs 0.1vs TIO62.5/25 µg · wk 24 · n 400NCT01777334
3 other results
  • 0.1 vs -0.0 62.5/25 µg · wk 12.14 · n 224 · Phase 3 · primary NCT01899742
  • 0.2 vs 0.2 wk 12 · n 309 · Phase 3 · secondary NCT02487446
  • 0.2 vs 0.2 wk 12 · n 314 · Phase 3 · secondary NCT02487446
SGRQ total, change—Not reported—Trial running · NCT06474039
TDI focal score—Not reported—Trial running · NCT06474039

Moderate or severe exacerbations, annualised rate

fluticasone furoate/​vilanterol
—Not reported
Umeclidinium/​Vilanterol
—Trial running · NCT06474039

Trough FEV1, change

fluticasone furoate/​vilanterol
—Not reported
Umeclidinium/​Vilanterol
0.2 vs 0.1vs TIO62.5/25 µg · wk 24 · n 400NCT01777334
3 other results
  • 0.1 vs -0.0 62.5/25 µg · wk 12.14 · n 224 · Phase 3 · primary NCT01899742
  • 0.2 vs 0.2 wk 12 · n 309 · Phase 3 · secondary NCT02487446
  • 0.2 vs 0.2 wk 12 · n 314 · Phase 3 · secondary NCT02487446

SGRQ total, change

fluticasone furoate/​vilanterol
—Not reported
Umeclidinium/​Vilanterol
—Trial running · NCT06474039

TDI focal score

fluticasone furoate/​vilanterol
—Not reported
Umeclidinium/​Vilanterol
—Trial running · NCT06474039
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

fluticasone furoate/vilanterol
Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants NCT01313676 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. fluticasone furoate/vilanterol: 0 of 4 rows · Umeclidinium/Vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricUmeclidinium/​Vilanterol
Dropout rate
11.7%62.5/25 µga
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
—62.5/25 µg once daily
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—
NCT02487446 · Phase 3 · registry result, not featured evidence
—27.5/12.5 Bid
NCT02487498 · Phase 3 · registry result, not featured evidence
6.9%62.5/25 µg
NCT01899742 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
4%62.5/25 µga
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
—62.5/25 µg once daily
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—
NCT02487446 · Phase 3 · registry result, not featured evidence
—27.5/12.5 Bid
NCT02487498 · Phase 3 · registry result, not featured evidence
2%62.5/25 µg
NCT01899742 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
Serious AEs
3.5%62.5/25 µga
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
1.7%62.5/25 µg once daily
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
3.8%
NCT02487446 · Phase 3 · registry result, not featured evidence
5%27.5/12.5 Bid
NCT02487498 · Phase 3 · registry result, not featured evidence
2.8%62.5/25 µg
NCT01899742 · Phase 3 · registry result, not featured evidence
0.5%62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
62.5/25 µga
headache 8.8%
nasopharyngitis 6.2%
cough 2.9%
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
62.5/25 µg once daily
nasopharyngitis 4%
headache 3.5%
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
chronic obstructive pulmonary disease 10.6%
nasopharyngitis 5.6%
oropharyngeal pain 2.9%
NCT02487446 · Phase 3 · registry result, not featured evidence
27.5/12.5 Bid
chronic obstructive pulmonary disease 14.8%
bronchitis 3.3%
sinusitis 1.8%
NCT02487498 · Phase 3 · registry result, not featured evidence
62.5/25 µg
nasopharyngitis 7.3%
headache 6.5%
NCT01899742 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 5%
NCT02014480 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Umeclidinium/Vilanterol

FEV1 Trough 0.205 vs 0.093 TIO L @ 24wk62.5/25 µg
absolute change · L
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 3 more results
0.074 vs -0.014 Tiotropium Bromide L @ 12.14wk62.5/25 µg
NCT01899742 · Phase 3 · registry result, not featured evidence
0.1891 vs 0.2043 Umeclidinium/Vilanterol L @ 12wk
NCT02487446 · Phase 3 · registry result, not featured evidence
0.2302 vs 0.245 Umeclidinium/Vilanterol L @ 12wk
NCT02487446 · Phase 3 · registry result, not featured evidence
FEV1 Wm0 6 h 0.276 vs 0.17 TIO L @ 24wk62.5/25 µg
absolute change · L
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
FEV1 71.7% (n=173) vs 53.8% (n=171) UMEC @ 0wk62.5/25 µg once daily
responder rate · % of participants
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 · converted to % from 124 participants as posted
show 1 more result
51% (n=202) vs 40.1% (n=202) UMEC @ 0.14wk*62.5/25 µg
Responder
NCT02014480 · Phase 3 · registry result, not featured evidence · converted to % from 103 participants as posted
FEV1 AUC(0-24h 0.2321 vs 0.2436 Umeclidinium/Vilanterol L @ 12wk
absolute change · L
NCT02487446 · Phase 3 · registry result, not featured evidence
show 1 more result
0.2321 vs 0.2436 Umeclidinium/Vilanterol L @ 12wk
NCT02487446 · Phase 3 · registry result, not featured evidence
FEV1 AUC 12-24h 0.2076 vs 0.2025 Umeclidinium/Vilanterol L @ 12wk
absolute change · L
NCT02487446 · Phase 3 · registry result, not featured evidence
FEV1 AUC0-12h 0.2543 vs 0.2848 Umeclidinium/Vilanterol L @ 12wk
absolute change · L
NCT02487446 · Phase 3 · registry result, not featured evidence
FEV1 Change 3 h 0.164 vs 0.091 Tiotropium Bromide L @ 12wk62.5/25 µg
absolute change · L
NCT01899742 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · Umeclidinium/Vilanterol's landscape